Latest Breaking News On - Webinar friday - Page 1 : comparemela.com
PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate hasdemonstrated efficacy in human models derived from the kidneys of patients with end-stage renal failure due to PKD[2] PKD is a life-changing disease affecting 1 in every 1,000 people[3] Half of the patient population withPKD will require a kidney transplant by the age of 60 due to the absence of impactful treatment options in this disease[4] PKD represents an addressable market of >US$10 billion p.a. and is an area of major commercial interest for the drug development industry[5] Pre-clinical models suggest that addressing the underlying cause ofPKD (the way that PYC's drug candidate works) could arrest the course of the disease in humans, enabling damaged kidneys to regenerate and restore function[6] PYC plans to accelerate this drug candidate into human trials in ~12 months - pursuing a potential high-velocity path through clinical trials
PerthWestern-australiaAustraliaCrown-biosciencesTwitterHuman-genetics-researchLinkedinDrug-administrationPolycystic-kidney-diseaseWebinar-fridayAutosomal-dominant-polycystic-kidney-diseaseInvestigational-new-drug